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tainty (i.e. expected value of perfect partial information; EVPPI).
To perform an EVPPI, two-stage sampling from the original
model is required. In practice, it is often not possible to perform
an EVPPI because of computer time constraints. OBJECTIVES:
The aim of this study is to investigate the usefulness and feasi-
bility of constructing a metamodel to estimate the EVPPI for
individual model parameters. METHODS: The metamodel was
based on a cost-effectiveness Markov model with 5000 iterations
for the treatment of patients with chronic obstructive pulmonary
disease. The metamodel constituted a linear regression, using the
net monetary beneﬁt of the 5000 simulations as the dependent
variable and the input values of the model parameters (e.g. prob-
abilities for exacerbations, hospital admissions, etc.) as indepen-
dent variables. This regression model was used to calculate the
EVPPI for each individual input parameter of the original cost-
effectiveness model. RESULTS: The EVPI was €3053. The analy-
sis showed that the regression-based metamodel provided a good
ﬁt of the original model. The adjusted R2 of the regression model
was 98%. The results obtained with the metamodel closely
resembled the results of a two-stage sampling EVPPI based on
the original model. CONCLUSIONS: In this study, regression-
based metamodel provided reliable estimates of the EVPPI. We
conclude that for cost-effectiveness models that meet the linear-
ity criterion, regression based metamodelling promises to be a
very efﬁcient and timesaving approach for the calculation of the
VOI for individual model parameters.
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UNCONDITIONAL POWER FOR SECONDARY OBJECTIVES IN
A CLINICAL TRIAL
Wang J, Irish WD
RTI Health Solutions, Research Triangle Park, NC, USA
OBJECTIVES: Sample size estimation in controlled clinical trials
is determined to insure that the primary objective can be
achieved with certain probability (i.e., power) based on the avail-
able information and study assumptions. Power to achieve sec-
ondary objectives is usually based on the sample size calculated
for the primary objective. If the secondary objectives are evalu-
ated on a sub-sample of the study population, then the sample
size becomes a random variable and power is calculated condi-
tioned on the average of sample sizes (i.e., conditional power).
This may prove problematic when the sample size for the sec-
ondary objectives is different from its mean. We present a
method to calculate unconditional power (i.e., power taking into
consideration sample size variability) in the situation where sec-
ondary objectives are evaluated on a sub-sample of the study
population. METHODS: The joint distribution of the test sta-
tistics and the sample size for the secondary objectives was con-
sidered. Based on the joint distribution, unconditional power of
the statistical tests for the secondary objectives was deﬁned. The
relationship between unconditional power and traditional power
condition on the expectation of the sample size was then
explored. RESULTS: By analytical reasoning, we found that con-
ditional power is higher than unconditional power when z-test
is used to test the equivalence of two population means with
known standard deviation at signiﬁcant level 0.05. Results can
be generalized to other types of statistical tests where the type I
error rate is 0.05. CONCLUSIONS: Under the design speciﬁca-
tions studied, conditional power was consistently greater than
the true power. This may give the researcher an overly optimistic
conﬁdence in achieving study results. We will present further
results under different design speciﬁcations and will highlight sit-
uations where conditional power can be used with application
to pharmacoeconomic outcomes.
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Atrial Fibrillation (AF) presents gross economic problem for
health care payers. Atrial based pacing is an accepted method 
of treatment of bradycardia-tachycardia syndrome (BRTS).
OBJECTIVES: to compare resource utilization and costs of care
in BRTS before and after atrial based pacemaker implanta-
tion. METHODS: Observational, retrospective, unicenter study
included 145pts (84F; 61M; mean age 68,5) with BRTS, parox-
ysmal AF and atrial based pacing system (AAI 64,8%; DDD
35,2%) implanted during one year. The data on utilized
resources were collected in time window: from 1 year before
implantation to 3 years after implantation. The costs were cal-
culated from the public health care payer perspective. RESULTS:
During the 3 years after implantation 20 patients died (13.8%)
and the cost analysis was performed among survivors. At least
one AF episode was reported in 103pts (82.4%) and 19 (15.2%)
had chronic AF at the end of study period. There were 338 AF
related hospitalizations before implantation (mean 2.7 per year,
per patient) compared to 423 (during 3 years; mean 1.13 per
year, per patient; Wilcoxon test p < 0.001). The distribution of
costs before implantation was: hospitalizations 82.0%, drugs
10.7%, consultations 4.1%, AF complications (mainly stroke)
3.2% and after implantation: hospitalizations 38.3%, followed
by drugs 24.4%, pacing complications costs 21.1%, consulta-
tions 6.1%, pacemaker follow-up 4.2% and AF complications
5.9%. The mean annual cost of care of AF decreased after
implantation from 3138 PLN (~1569 Euro PPP) to 1923 PLN
(~961 Euro PPP) (p < 0.001) and the savings were mainly asso-
ciated with lower hospitalization rate which was not only eco-
nomic but also clinical proﬁt. CONCLUSIONS: Atrial based
pacing decreases number of hospitalizations and overall costs of
therapy in bradycardia-tachycardia syndrome. Hospitalizations
due to AF represent the major cost driver in group of patients
with brady-tachy syndrome.
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OBJECTIVES: The term cerebrovascular disease designates any
abnormality of the brain resulting from a pathologic process of
the blood vessels. Medical and neurological complications after
stroke or transient ischemic attack have a high economic impact.
The objectives of the study were to assess the social costs of sub-
jects with cerebrovascular disease, almost one transient ischemic
attack or stroke (case) and to compare the costs of these subjects
with the costs attributable to subjects without cerebrovascular
disease (control). METHODS: Data were collected from a pop-
ulation based naturalistic prospective survey (a representative
sample of the Italian general population aged from 40 to 79
years). Subjects with cerebrovascular disease going to general
practitioners (GP) were enrolled. We matched each of them by
age and sex with controls. We conducted a Cost of Illness (COI)
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analysis from a societal perspective with a 3 month time horizon.
Direct medical costs (hospitalizations, drug therapies, specialist
visits, diagnostics, and laboratory exams) were quantiﬁed using
the National Health Service tariffs expressed in Euro 2005.
RESULTS: 220 patients were enrolled, 110 cases matched with
110 controls. The mean age was 66.0 years, 57.3% were male.
The mean total cost per patient-month was Euro 380.4 com-
pared to Euro 164.4 for cases and controls, respectively (P <
0.0001). On average, direct medical cost per patient-month was
estimated at Euro 368.6 in cases and Euro 149.8 in controls (P
< 0.0001). Hospitalizations accounted for the greatest propor-
tion of Health care costs in both groups, followed by drug ther-
apies (hospitalizations: 21.9% and 5.5%; drug therapies: 94.5%
and 68.2% in cases and controls, respectively). The working
ability reduction is higher in cases than in controls (P = 0.004).
CONCLUSION: The results of our analysis show that subjects
with cerebrovascular disease aged 40 to 79 years are more costly
than subjects without cerebrovascular diseases.
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OBJECTIVES: Clinical trials have shown that candesartan, an
angiotensin II receptor antagonist, improves survival and reduces
hospitalisation rates in patients with chronic heart failure (CHF)
and a reduced left ventricular ejection fraction (LVEF £ 40%).
This study assessed the cost-effectiveness of candesartan in the
management of CHF in Belgium. METHODS: Based on the 
outcomes (mortality, hospitalisation rate, cardiovascular events)
reported in the CHARM Programme (Candesartan in Heart
failure Assessment of Reduction in Mortality and morbidity), a
decision model was developed predicting the cost-effectiveness
of candesartan compared to placebo added to current standard
treatment (including diuretics, b-blockers, digoxin) of CHF. Two
populations with a LVEF £ 40% were analysed: those who were
intolerant of ACE-inhibitors (“alternative group”) and those
who were simultaneously treated with ACE-inhibitors (“added
group”). Direct costs from the health care payer’s perspective
(2004) were used. Effects were expressed as Life-Years gained
(LYG). The time horizon of the model was 3.14 years, based on
the follow up time in the CHARM programme, but also takes
into account that patients who survived the study period gain
life years and incur extra costs afterwards. An annual discount
of 3% was applied on costs and effects. The average cost per day
of candesartan (based on the average daily dose taken from the
CHARM-programme) was €1.06 in the “alternative” and €1.08
in the “added group”. RESULTS: The incremental cost-
effectiveness ratio was €1,214/LYG [95%CI €-8,365–€14,136]
in the “alternative” and €2,310/LYG [95%CI €425–€3,920] in
the “added” group. Sensitivity analysis showed the robustness of
the results. Monte Carlo analysis showed that, using a threshold
of €20,000/LYG, candesartan was cost-effective in 93.4% in the
“alternative” and in 99.8% in the “added” group. CONCLU-
SIONS: Administering candesartan to Belgian patients with a
LVEF £ 40% whether or not they are treated with ACE-
inhibitors seems cost-effective from the health care payer’s 
perspective.
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OBJECTIVE: To estimate the long-term economic and health
impact of managing bradycardia with DDDR-MVP instead of
standard dual chamber pacing (DDDR) in France. DDDR-MVP
can reduce the amount of ventricular pacing. This may be advan-
tageous since previous studies have shown that more frequent
pacing of the ventricle increases the risk for heart failure and
atrial ﬁbrillation. METHODS: A discrete event simulation was
developed to estimate effects over ﬁve years. Identical patient
pairs were created, one received DDDR-MVP, the other DDDR.
During the simulation, each patient may develop post-operative
complications, pacemaker syndrome, heart failure, atrial ﬁbril-
lation (which may become chronic and require anticoagulants),
or have a stroke. The risk proﬁles depend on the patient’s char-
acteristics, device type and cumulative ventricular pacing. The
cumulative proportion of time receiving ventricular pacing is
based on data collected during a randomized, single-blind cross-
over trial of these devices. Risk functions for the association of
ventricular pacing with heart failure and atrial ﬁbrillation were
based on published data from the MOST trial. Life expectancy
is assumed the same with either device. Costs obtained from hos-
pitalization (re-operation, heart failure, stroke), and anticoagu-
lation, are reported in 2004 € and discounted at 3%. Each
analysis was based on 100 replications. Sensitivity analyses
covered all inputs and assumptions. RESULTS: Within 5 years,
29.1% of the patients in each cohort died. Discounted costs over
5 years were about €13,000 per patient; despite the higher initial
cost of DDDR-MVP mean additional cost was only €274 per
patient. DDDR-MVP is predicted to increase QALY by a mean
0.05 years, yielding a mean cost-effectiveness ratio of
€5,360/QALY. Sensitivity analyses showed the results were con-
sistent over a wide range of values. CONCLUSION: Based on
these 5-year estimates, the additional health beneﬁts of MVP
provide very attractive value for patients with sinoatrial-node
disease or intermittent atrioventricular block.
Utility Based Patient Reported Outcomes
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ALGORITHMS FOR ESTIMATING EQ-5D AND SF-6D VALUES
FROM THE INFLAMMATORY BOWEL DISEASE
QUESTIONNAIRE IN PATIENTS WITH CROHN’S DISEASE
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OBJECTIVES: To examine the relationship between the Inﬂam-
matory Bowel Disease questionnaire (IBDQ) total score and
measures of utility (EQ-5D and the SF-6D scores), and to esti-
mate algorithms to map the two utility values from IBDQ scores.
METHODS: A large dataset, from ENACT I and II multina-
tional, randomized, placebo controlled clinical trials in moder-
ate to severe Crohn’s disease, provided contemporaneous patient
responses to all three questionnaires. Paired observations from
multiple time-points for patients from both trials were combined
in the analysis. The mean utility scores by IBDQ score deciles
were estimated. Spearman correlation coefﬁcients were calcu-
